[go: up one dir, main page]

PE20080742A1 - Perfil genico y procedimiento de identificacion - Google Patents

Perfil genico y procedimiento de identificacion

Info

Publication number
PE20080742A1
PE20080742A1 PE2007000676A PE2007000676A PE20080742A1 PE 20080742 A1 PE20080742 A1 PE 20080742A1 PE 2007000676 A PE2007000676 A PE 2007000676A PE 2007000676 A PE2007000676 A PE 2007000676A PE 20080742 A1 PE20080742 A1 PE 20080742A1
Authority
PE
Peru
Prior art keywords
immunotherapy
gene profile
cancer
identification procedure
gene
Prior art date
Application number
PE2007000676A
Other languages
English (en)
Inventor
Vincent Brichard
James Scott Clark
Thierry Coche
Swann Romain Jean-Thomas Gaulis
Olivier Gruselle
Frederic Lehmann
Jamila Louahed
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0610949A external-priority patent/GB0610949D0/en
Priority claimed from GB0700761A external-priority patent/GB0700761D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of PE20080742A1 publication Critical patent/PE20080742A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)

Abstract

REFERIDA A UN PERFIL GENICO INDICATIVO DE UN PROBABILIDAD AUMENTADA DE UNA RESPUESTA A UNA INMUNOTERAPIA QUE COMPRENDE LA REGULACION DIFERENCIAL DE AL MENOS UN GEN DE ACTIVACION INMUNE, DONDE LA INMUNOTERAPIA ES UNA INMUNOTERAPIA DE CANCER ESPECIFICA DEL ANTIGENO MAGE QUE SON ANTIGENOS CODIFICADOS POR LA FAMILIA DE GENES DE ANTIGENO ASOCIADOS A MELANOMA. TAMBIEN ESTA REFERIDA A UN PROCEDIMIENTO DE IDENTIFICACION DE DICHO PERFIL GENICO Y A UN KIT. EL PERFIL GENICO DE UN PACIENTE, EL PROCEDIMIENTO DE IDENTIFICACION DEL PERFIL GENICO Y EL KIT SON UTILES EN LA IDENTIFICACION DE PACIENTES CON CANCER QUE ES PROBABLE QUE RESPONDAN A LA INMUNOTERAPIA APROPIADA
PE2007000676A 2006-06-02 2007-05-31 Perfil genico y procedimiento de identificacion PE20080742A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0610949A GB0610949D0 (en) 2006-06-02 2006-06-02 Method
GB0700761A GB0700761D0 (en) 2007-01-15 2007-01-15 Method

Publications (1)

Publication Number Publication Date
PE20080742A1 true PE20080742A1 (es) 2008-08-06

Family

ID=38801855

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2007000676A PE20080742A1 (es) 2006-06-02 2007-05-31 Perfil genico y procedimiento de identificacion

Country Status (15)

Country Link
US (1) US20100021424A1 (es)
EP (23) EP2390364A1 (es)
JP (1) JP2009538607A (es)
KR (1) KR20090017655A (es)
AR (1) AR061136A1 (es)
AU (1) AU2007256383B2 (es)
BR (1) BRPI0712497A2 (es)
CA (1) CA2653949A1 (es)
CL (1) CL2007001571A1 (es)
EA (1) EA200802242A1 (es)
ES (1) ES2539042T3 (es)
MX (1) MX2008015372A (es)
PE (1) PE20080742A1 (es)
TW (1) TW200817680A (es)
WO (1) WO2007140958A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2227558A1 (en) * 2007-11-30 2010-09-15 GlaxoSmithKline Biologicals SA Method for classifying cancer patients as responder or non-responder to immunotherapy
GB0816867D0 (en) * 2008-09-15 2008-10-22 Glaxosmithkline Biolog Sa Method
GB2466025A (en) * 2008-12-08 2010-06-09 Univ Francois Rabelais De Tour C3/ITGAM polymorphisms and cancer prognosis
GB0917457D0 (en) * 2009-10-06 2009-11-18 Glaxosmithkline Biolog Sa Method
EP2513336B1 (en) * 2009-12-16 2016-03-02 Hitachi Chemical Co., Ltd. Method for characterizing host immune function by ex vivo induction of offensive and defensive immune markers
EP2380991A1 (en) 2010-04-20 2011-10-26 Universitätsklinikum Hamburg-Eppendorf Method of determining the metastatic potential of a tumor
CN106978480A (zh) * 2010-09-15 2017-07-25 阿尔玛克诊断有限公司 用于癌症的分子诊断试验
KR101287600B1 (ko) * 2011-01-04 2013-07-18 주식회사 젠큐릭스 초기유방암의 예후 예측용 유전자 및 이를 이용한 초기유방암의 예후예측 방법
US9926604B2 (en) 2011-10-14 2018-03-27 The Regents Of The University Of California Multiplex PCR-based testing of cutaneous squamous cell carcinoma and pseudoepitheliomatous hyperplasia and methods for distinguishing the same
US11242564B2 (en) * 2012-07-12 2022-02-08 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes
JO3519B1 (ar) 2013-01-25 2020-07-05 Amgen Inc تركيبات أجسام مضادة لأجل cdh19 و cd3
WO2015077717A1 (en) 2013-11-25 2015-05-28 The Broad Institute Inc. Compositions and methods for diagnosing, evaluating and treating cancer by means of the dna methylation status
US11725237B2 (en) 2013-12-05 2023-08-15 The Broad Institute Inc. Polymorphic gene typing and somatic change detection using sequencing data
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
CA2953703A1 (en) * 2014-07-03 2016-01-07 University Of Virginia Patent Foundation Systems and methods for identifying and profiling muscle patterns
US20170298443A1 (en) * 2014-09-25 2017-10-19 Moffitt Genetics Corporation Prognostic tumor biomarkers
WO2016100975A1 (en) * 2014-12-19 2016-06-23 Massachsetts Institute Ot Technology Molecular biomarkers for cancer immunotherapy
WO2016100977A1 (en) 2014-12-19 2016-06-23 The Broad Institute Inc. Methods for profiling the t-cel- receptor repertoire
JP6489900B2 (ja) * 2015-03-30 2019-03-27 株式会社ジャパンディスプレイ 入力装置及び表示装置
CR20200476A (es) 2015-05-20 2020-12-02 Dana Farber Cancer Inst Inc ANTÍGENOS COMPARTIDOS (Divisional 2017-0584)
WO2017011623A1 (en) * 2015-07-14 2017-01-19 Atossa Genetics Inc. Transpapillary methods and compositions for treating breast disorders
WO2017040520A1 (en) 2015-08-31 2017-03-09 Hitachi Chemical Co., Ltd. Molecular methods for assessing urothelial disease
WO2018140391A1 (en) 2017-01-24 2018-08-02 The Broad Institute, Inc. Compositions and methods for detecting a mutant variant of a polynucleotide
JP7457642B2 (ja) 2017-04-03 2024-03-28 ビオンテック ユーエス インコーポレイテッド タンパク質抗原およびその使用
TW201930340A (zh) 2017-12-18 2019-08-01 美商尼恩醫療公司 新抗原及其用途
CA3103983A1 (en) 2018-06-19 2019-12-26 Biontech Us Inc. Neoantigens and uses thereof
GB201908565D0 (en) * 2019-06-14 2019-07-31 Cray Innovation Ab Method of stratifying subjects into sub-groups for therapeutic treatment
CN114540504B (zh) * 2022-04-27 2022-07-08 广州万德基因医学科技有限公司 用于预测肺鳞癌患者免疫疗效的标志物组及系统

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1001034B (el) * 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
EP0761231B1 (en) 1992-06-25 2000-01-12 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine composition containing adjuvants
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
EP0772619B2 (en) 1994-07-15 2010-12-08 The University of Iowa Research Foundation Immunomodulatory oligonucleotides
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
DE69942214D1 (de) 1998-02-05 2010-05-12 Glaxosmithkline Biolog Sa Verfahren zur Reinigung oder Herstellung der MAGE Protein
DK1104306T3 (da) 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
CN1201004C (zh) 1999-01-29 2005-05-11 考丽克萨有限公司 HER－2/neu融合蛋白
JP2002538787A (ja) 1999-03-11 2002-11-19 スミスクライン ビーチャム バイオロジカルズ ソシエテ アノニム 新規化合物
TR200103018T2 (tr) 1999-04-19 2002-02-21 Beecham Biologicals S.A. Smithkline İmmünostimülatör oligonükleotid ve saponin içeren katkı bileşikleri.
PL209127B1 (pl) 2000-02-23 2011-07-29 Smithkline Beecham Biolog Środek farmaceutyczny do stosowania w immunoterapeutycznym leczeniu raka i sposób diagnozowania u pacjenta obecności lub podatności na raka
AUPR077900A0 (en) * 2000-10-13 2000-11-09 Tvw Telethon Institute For Child Health Research Immunodiagnosis
US20020076469A1 (en) * 2000-10-31 2002-06-20 Colgate-Palmolive Company Composition and method
JP2004529888A (ja) * 2001-02-26 2004-09-30 ゲゼルシャフト フュア ビオテヒノロジッシェ フォルシュング エムベーハー （ゲーベーエフ） インターフェロン調節因子−１／ヒトエストロゲン受容体融合タンパク質および癌を治療するためのその使用
WO2002076469A1 (en) * 2001-03-27 2002-10-03 Baylor College Of Medicine A novel technology of intracellular delivery of dna oligonucleotides to improve drug activity
DE10127572A1 (de) * 2001-05-30 2002-12-05 Pathoarray Gmbh Werkzeuge zur Diagnostik, molekularen Definition und Therapieentwicklung chronischer entzündlicher Gelenkerkrankungen
US7229774B2 (en) * 2001-08-02 2007-06-12 Regents Of The University Of Michigan Expression profile of prostate cancer
JP4424987B2 (ja) * 2001-09-20 2010-03-03 ボード オブ リージェンツ， ザ ユニバーシティ オブ テキサス システム Ｅｌｉｓａアッセイを用いた循環する治療抗体、抗原および抗原／抗体複合体の測定
WO2003050257A2 (en) * 2001-12-06 2003-06-19 University Of Florida Targeting leukemia cells
EP1482795B1 (en) 2002-02-04 2009-11-11 Corixa Corporation New immunoeffector compounds
US20040248151A1 (en) * 2002-04-05 2004-12-09 Ventana Medical Systems, Inc. Method for predicting the response to HER2-directed therapy
US20060147477A1 (en) 2002-06-11 2006-07-06 Glaxo Group Limited Immunogenic compositions
US20040231909A1 (en) * 2003-01-15 2004-11-25 Tai-Yang Luh Motorized vehicle having forward and backward differential structure
US20050054496A1 (en) * 2003-02-25 2005-03-10 Harms Robert E. Coated weight plates, dumbbells and method of manufacture
EP1605811A4 (en) * 2003-02-28 2008-06-11 Bayer Pharmaceuticals Corp EXPRESSION PROFILES FOR BREAST CANCER AND METHODS OF USE
WO2005098037A1 (en) * 2003-03-07 2005-10-20 Arcturus Bioscience, Inc. Breast cancer signatures
WO2004081564A1 (en) 2003-03-14 2004-09-23 Peter Maccallum Cancer Institute Expression profiling of tumours
US20040241725A1 (en) * 2003-03-25 2004-12-02 Wenming Xiao Lung cancer detection
US7598287B2 (en) * 2003-04-01 2009-10-06 Medical College Of Georgia Research Institute, Inc. Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities
WO2004105573A2 (en) * 2003-05-21 2004-12-09 The Wistar Institute Of Anatomy And Biology Method of diagnosis of cancer based on gene expression profiles in cells
EP1631689A2 (en) * 2003-05-28 2006-03-08 Genomic Health, Inc. Gene expression markers for predicting response to chemotherapy
KR101126560B1 (ko) 2003-05-30 2012-04-05 도꾜 다이가꾸 약제 반응 예측 방법
US20050100933A1 (en) * 2003-06-18 2005-05-12 Arcturus Bioscience, Inc. Breast cancer survival and recurrence
KR101431312B1 (ko) * 2003-06-27 2014-08-20 인터내셔널 인스티튜트 오브 캔서 이무놀로지 인코퍼레이티드 Ｗｔ1 백신 적응 환자의 선택 방법
PL1668152T3 (pl) * 2003-08-28 2009-06-30 Ipsogen Identyfikacja sygnatury ekspresji genów ERBB2 w rakach sutka
JP2007507243A (ja) 2003-10-03 2007-03-29 バイエル・フアーマシユーチカルズ・コーポレーシヨン 遺伝子発現プロファイルおよび使用方法
US20070110710A1 (en) * 2003-11-05 2007-05-17 New England Medical Center Hospitals, Inc. Treatment with immunoregulatory t cells
WO2005054496A1 (ja) * 2003-12-02 2005-06-16 Orient Cancer Therapy Co., Ltd. 細胞動態の検査方法
WO2005059543A1 (en) * 2003-12-12 2005-06-30 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled receptor h963 (h963)
WO2005075680A1 (ja) * 2004-02-09 2005-08-18 Fuso Pharmaceutical Industries, Ltd. 核酸検出方法およびその利用
US20060195266A1 (en) 2005-02-25 2006-08-31 Yeatman Timothy J Methods for predicting cancer outcome and gene signatures for use therein
US7332281B2 (en) * 2004-04-27 2008-02-19 Sagres Discovery, Inc. Therapeutic targets in cancer
DK1782070T3 (da) * 2004-06-17 2011-01-03 Mannkind Corp Tumorassocieret antigenprofiler i cancerdiagnostik og immunterapi
US8053197B2 (en) * 2004-07-30 2011-11-08 Oregon Health & Science University Methods for detecting and treating autoimmune disorders
WO2006054129A1 (en) 2004-11-19 2006-05-26 Institut Gustave Roussy Improved treatment of cancer by double-stranded rna
US20060110371A1 (en) * 2004-11-23 2006-05-25 Institut Pasteur Control of indoleamine 2,3 deoxygenase expression and activity
BRPI0518734A2 (pt) * 2004-11-30 2008-12-02 Veridex Llc prognàstico de cÂncer de pulmço
US20070059720A9 (en) * 2004-12-06 2007-03-15 Suzanne Fuqua RNA expression profile predicting response to tamoxifen in breast cancer patients
WO2006073982A2 (en) * 2004-12-30 2006-07-13 Regents Of The University Of California Bispecific molecule comprising ligands for cell-surface protein and t-cell surface protein
US7666595B2 (en) 2005-02-25 2010-02-23 The Brigham And Women's Hospital, Inc. Biomarkers for predicting prostate cancer progression
GB0504302D0 (en) 2005-03-02 2005-04-06 Univ Dublin Markers for melanoma
JP2008534002A (ja) 2005-04-01 2008-08-28 エヌシィーシィー テクノロジー ベンチャーズ ピィーティーイー．リミテッド 乳癌の分類に関する材料および方法
JP2008535853A (ja) * 2005-04-07 2008-09-04 ノバルティス ヴァクシンズ アンド ダイアグノスティクス インコーポレイテッド 癌関連遺伝子
EP1869222A4 (en) * 2005-04-15 2010-01-20 Oncomethylome Sciences S A METHYLATION MARKERS FOR THE DIAGNOSIS AND TREATMENT OF CANCER
EP1910564A1 (en) 2005-05-13 2008-04-16 Duke University Gene expression signatures for oncogenic pathway deregulation
US20070111257A1 (en) * 2005-07-07 2007-05-17 Kohne David E Improved protein expression comparison assay results and applications
EP1934599A1 (en) * 2005-10-11 2008-06-25 Merck Patent GmbH Egfr dependent modulation of chemokine expression and influence on therapy and diagnosis of tumors and side effects thereof
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method

Also Published As

Publication number Publication date
EA200802242A1 (ru) 2009-08-28
JP2009538607A (ja) 2009-11-12
EP2390368A1 (en) 2011-11-30
EP2390365A1 (en) 2011-11-30
EP2390355A1 (en) 2011-11-30
EP2390361A1 (en) 2011-11-30
EP2390366A1 (en) 2011-11-30
WO2007140958A3 (en) 2008-07-03
AU2007256383B2 (en) 2013-06-06
EP2390358A1 (en) 2011-11-30
EP2390364A1 (en) 2011-11-30
EP2390357A1 (en) 2011-11-30
TW200817680A (en) 2008-04-16
AR061136A1 (es) 2008-08-06
KR20090017655A (ko) 2009-02-18
EP2032719A2 (en) 2009-03-11
EP2392673A1 (en) 2011-12-07
AU2007256383A1 (en) 2007-12-13
WO2007140958A9 (en) 2009-11-26
EP2390362A1 (en) 2011-11-30
EP2392675A1 (en) 2011-12-07
EP2390367A1 (en) 2011-11-30
EP2392671A1 (en) 2011-12-07
BRPI0712497A2 (pt) 2012-09-18
EP2390363A1 (en) 2011-11-30
EP2390353A1 (en) 2011-11-30
EP2390354A1 (en) 2011-11-30
CA2653949A1 (en) 2007-12-13
EP2390359A1 (en) 2011-11-30
EP2390369A1 (en) 2011-11-30
EP2390356A1 (en) 2011-11-30
WO2007140958A2 (en) 2007-12-13
EP2392672A1 (en) 2011-12-07
ES2539042T3 (es) 2015-06-25
EP2258874B1 (en) 2015-03-18
EP2258874A1 (en) 2010-12-08
CL2007001571A1 (es) 2008-05-16
EP2390360A1 (en) 2011-11-30
MX2008015372A (es) 2009-03-23
US20100021424A1 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
PE20080742A1 (es) Perfil genico y procedimiento de identificacion
EA201590833A1 (ru) Антитела для лечения и профилактики болезни альцгеймера и их применение
ATE466084T1 (de) Hla-a24-restringiertes krebsantigenpeptid
EP2228072A4 (en) CANCER VACCINE COMPOSITION
MX2018010361A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
PH12014502507A1 (en) Anti-angiogenesis therapy for the treatment of breast cancer
CR9315A (es) Metodos y sistemas para el diagnostico, pronostico y seleccion del tratamiento de la leucemia
TNSN05300A1 (en) Treatment with anti-vegf antibodies
PL2733493T3 (pl) Sposób prognozowania in vitro progresji nowotworu i rezultatu u pacjenta oraz środki do przeprowadzenia wymienionego sposobu
EP3064584A3 (en) Micro rna-based methods and compositions for the diagnosis, prognosis and treatmentof gastric cancer
CY1120096T1 (el) Αναγνωριση αντιγονων που σχετιζονται με ογκο για διαγνωση και θεραπεια
AR102538A1 (es) Métodos de selección de la línea celular t y donante de la misma para la terapia adoptiva celular
WO2008146309A3 (en) Genetic variants on chr 5pl2 and 10q26 as markers for use in breast cancer risk assessment, diagnosis, prognosis and treatment
MX2009010439A (es) Variantes geneticas de chr2 y chr16 como marcadores para el uso en valoracion, diagnosis, prognosis y tratamiento de riesgo de cancer de mama.
MX2019003148A (es) Base de datos, de datos moleculares, omicos, de inmunoterapia, metabolicos, epigeneticos y clinicos, integrados.
EP3299387A3 (en) Identification of tumor-associated markers for diagnosis and therapy
EA201400710A1 (ru) Способы детекции признаков заболеваний или состояний в жидкостях организма
CA2962075C (en) Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
AR054536A1 (es) Terapia de combinacion de anticuerpo anti- ctla -4 y oligodesoxinucleotido sintetico que contiene motivo cgp para el tratamiento del cancer
UA106756C2 (uk) Генетичні маркери, асоційовані з відповіддю на інтерферон-альфа
WO2010056351A3 (en) Gene expression classifiers for relapse free survival and minimal residual disease improve risk classification and out come prediction in pedeatric b-precursor acute lymphoblastic leukemia
ES2422739T3 (es) Composición para el diagnóstico, prevención o tratamiento de enfermedades relacionadas con células que expresan IL-8 o GRO-, que comprende MSC de UCB
DE602005023488D1 (de) Tumorassoziierte antigenprofile in der krebsdiagnostik und immuntherapie
MX2019005065A (es) Metodos de tratamiento de pacientes con cancer con inhibidores de farnesiltransferasa.
EP2420509A3 (en) Novel marker genes for regulatory T cells from human blood

Legal Events

Date Code Title Description
FA Abandonment or withdrawal